Presented updated data for bexobrutideg (NX-5948) at EHA2025 and ICML-18, demonstrating a favorable safety profile and ...

Investing.com -- Nurix Therapeutics Inc (NASDAQ: NRIX) reported better-than-expected financial results for its fiscal second quarter ended May 31, 2025, driven by significant milestone payments from ...

About the Setrusumab Phase 3 Program Ultragenyx is developing setrusumab in pediatric and young adult patients across OI sub-types I, III and IV with two late-stage studies: the pivotal Phase 2/3 ...

Lynas could turn attention to Brazil's ionic clay deposits as it seeks to mine more heavy rare earths, lighting a ... Read ...